AstraZeneca has signed a licence agreement with a small UK-based biotech company for a slate of COVID antibody therapies, the Anglo-Swedish pharmaceutical giant said on Tuesday.
The experimental antibody therapies - developed by RK Bio, include those designed to target people with compromised immune systems - such as AstraZeneca's own antibody cocktail, Evusheld, which is already approved in multiple countries.
“WATCH: The latest videos from the Star”
![[PHOTOS] Elgeyo Marakwet landslide victims arrive in Eldoret for care](/_next/image?url=https%3A%2F%2Fcdn.radioafrica.digital%2Fimage%2F2025%2F11%2F425460d9-7ff1-4975-8a1f-cd0aaefb7812.jpg&w=3840&q=100)